131 related articles for article (PubMed ID: 25685063)
1. Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines.
Lam LT; Zhang H; Xue J; Leverson JD; Bhathena A
Cancer Cell Int; 2015; 15(1):5. PubMed ID: 25685063
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
4. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma.
Golla C; Bilal M; Dwucet A; Bader N; Anthonymuthu J; Heiland T; Pruss M; Westhoff MA; Siegelin MD; Capanni F; Wirtz CR; Kast RE; Halatsch ME; Karpel-Massler G
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439278
[TBL] [Abstract][Full Text] [Related]
6. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
8. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
9. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
11. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent.
Mohamad Anuar NN; Nor Hisam NS; Liew SL; Ugusman A
Front Pharmacol; 2020; 11():564108. PubMed ID: 33381025
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
13. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
14. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
15. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.
Zhang H; Guttikonda S; Roberts L; Uziel T; Semizarov D; Elmore SW; Leverson JD; Lam LT
Oncogene; 2011 Apr; 30(16):1963-8. PubMed ID: 21132008
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
17. Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway.
Asdemir A; Özgür A
Med Oncol; 2024 Mar; 41(4):83. PubMed ID: 38436810
[TBL] [Abstract][Full Text] [Related]
18. Arenobufagin Induces Apoptotic Cell Death in Human Non-Small-Cell Lung Cancer Cells via the Noxa-Related Pathway.
Ma L; Zhu Y; Fang S; Long H; Liu X; Liu Z
Molecules; 2017 Sep; 22(9):. PubMed ID: 28892004
[TBL] [Abstract][Full Text] [Related]
19. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1.
Ow TJ; Fulcher CD; Thomas C; Broin PÓ; López A; Reyna DE; Smith RV; Sarta C; Prystowsky MB; Schlecht NF; Schiff BA; Rosenblatt G; Belbin TJ; Harris TM; Childs GC; Kawachi N; Guha C; Gavathiotis E
Oncotarget; 2019 Jan; 10(4):494-510. PubMed ID: 30728900
[TBL] [Abstract][Full Text] [Related]
20. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]